Logo image
Impact of COVID-19 on Hepatitis B Screening in Sierra Leone: Insights from a Community Pharmacy Model of Care
Journal article   Open access   Peer reviewed

Impact of COVID-19 on Hepatitis B Screening in Sierra Leone: Insights from a Community Pharmacy Model of Care

Manal Ghazzawi, Lawrence S. Babawo, Amir M. Mohareb, Peter B. James, Sahr A. Yendewa, Samuel P.E. Massaquoi, Peterlyn E. Cummings, Sulaiman Lakoh, Robert A. Salata and George A. Yendewa
IJID regions, Vol.9, pp.7-13
12/2023
pdf
Impact of COVID-19 on Hepatitis B Screening in Sierra Leone: Insights from a Community Pharmacy Model of Care755.68 kBDownloadView
Accepted Journal Pre-proof Open Access CC BY-NC-ND V4.0
url
Impact of COVID-19 on Hepatitis B Screening in Sierra Leone: Insights from a Community Pharmacy Model of CareView
Published (Version of record) Open CC BY-NC-ND V4.0

Related links

Metrics

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Abstract

Hepatitis B virus Screening Diagnosis COVID-19 Sierra Leone
Background There are limited studies evaluating the impact of COVID-19-related interruptions on hepatitis B virus (HBV) screening in endemic countries in Sub-Saharan Africa. Methods We conducted a retrospective study of HBV testing in a community pharmacy in Freetown, Sierra Leone, from October 1, 2019, through September 30, 2022. We compared participant characteristics using Pearson's chi-square test. We evaluated trends in HBV screening and diagnosis using one-way ANOVA with Tukey's or Dunnett's post-test. Findings Of 920 individuals screened, 161 had detectable HBsAg (seroprevalence 17.5% [95% CI 14.9-20.4]). There was a 100% decrease in HBV screening during January-June of 2020; however, screening increased by 27% and 23% in the first and second year after COVID-19, respectively. Mean quarterly tests showed a significant upward trend: 55 ± 6 tests during January-March (baseline), 74 ± 16 tests during April-June, 101 ± 3 tests during July-September, and 107 ± 17 tests during October-December (one-way ANOVA test for trend, F=7.7, p = 0.0254) but not the mean quarterly number of people diagnosed with HBV (F = 0.34, p = 0.7992). Interpretation Community-based HBV screening dramatically improved following temporary disruptions related to COVID-19. Seasonal variation in HBV screening, but not HBV diagnosis, may have implications for HBV elimination efforts in Sierra Leone and other West African countries.

Details

Logo image